Sandoz and Pear Therapeutics announce Pear will solely commercialize reSET? and reSET-O
[caption id="attachment_9277" align="aligncenter" width="747"]
Press Release[/caption]
Sandoz, a Novartis division, and Pear Therapeutics announced today that Pear will assume sole responsibility to commercialize Pear?s prescription digital therapeutics (PDTs), reSET? and reSET-O?, new therapies for the treatment of substance use disorder (SUD) and opioid use disorder (OUD). Pear will market these PDTs as part of its deep commitment to pioneering software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers.
Pear and Sandoz previously signed a co-promotion agreement and accordingly, Pear has already built a standalone commercial infrastructure capable of supporting reSET, reSET-O and future PDTs.? Sandoz believes that Pear is now well-suited to continue to bring these important digital therapeutics to patients, HCPs, and payers, and will continue to partner with Pear and support the commercial efforts through a transition period to ensure uninterrupted patient access to reSET and reSET-O.
Sandoz decision to transition commercialization responsibilities for reSET and reSET-O is part of Sandoz transformation and subsequent leadership change, which has resulted in a reinforced focus on and capital allocation for Sandoz core business.
Sandoz has made important strides introducing the new therapeutic category of PDTs to physicians and behavioral health counselors. Through their efforts, prescribers are now writing increasingly more scripts and more patients living with addiction are having access to treatment through the use of PDTs.
Press Release[/caption]
Sandoz, a Novartis division, and Pear Therapeutics announced today that Pear will assume sole responsibility to commercialize Pear?s prescription digital therapeutics (PDTs), reSET? and reSET-O?, new therapies for the treatment of substance use disorder (SUD) and opioid use disorder (OUD). Pear will market these PDTs as part of its deep commitment to pioneering software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers.
Pear and Sandoz previously signed a co-promotion agreement and accordingly, Pear has already built a standalone commercial infrastructure capable of supporting reSET, reSET-O and future PDTs.? Sandoz believes that Pear is now well-suited to continue to bring these important digital therapeutics to patients, HCPs, and payers, and will continue to partner with Pear and support the commercial efforts through a transition period to ensure uninterrupted patient access to reSET and reSET-O.
Sandoz decision to transition commercialization responsibilities for reSET and reSET-O is part of Sandoz transformation and subsequent leadership change, which has resulted in a reinforced focus on and capital allocation for Sandoz core business.
Sandoz has made important strides introducing the new therapeutic category of PDTs to physicians and behavioral health counselors. Through their efforts, prescribers are now writing increasingly more scripts and more patients living with addiction are having access to treatment through the use of PDTs.
# # #
For further information, contact: Sandoz US Communications Leslie Pott +1 609 627 5287 leslie.pott@sandoz.com